Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure

Meeting report with video, highlights and slides of PACE-CME symposium held at ESC 2017 in Barcelona, more items to follow...

Episodes 1-3 of 3

  • Heart failure  Diabetes Time for a more unified approachHeart failure  Diabetes Time for a more unified approach
    Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure
    Heart failure & Diabetes: Time for a more unified approach
    • Stefan D. Anker MD
      Stefan D. Anker MD

      Stefan D. Anker MD

  • SGLT inhibition in cardiology What a cardiologist needs to knowSGLT inhibition in cardiology What a cardiologist needs to know
    Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure
    SGLT2 inhibition in cardiology: What a cardiologist needs to know
    • Naveed Sattar, MD
      Naveed Sattar, MD

      Naveed Sattar, MD

  • Management of CV Risk  TDM Implications of novel outcome trialsManagement of CV Risk  TDM Implications of novel outcome trials
    Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure
    Management of CV Risk & T2DM: Implications of novel outcome trials
    • John E Deanfield, MD
      John E Deanfield, MD

      John E Deanfield, MD

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free